 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...220221222223224225226227228229230...235236» |
- | 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Trial completion: ITACA-S: Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (clinicaltrials.gov) - Dec 12, 2013
P3, N=1100, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial termination, Metastases: SWOG-S0600: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy (clinicaltrials.gov) - Dec 11, 2013
P3, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Due to inadequate accrual, study was terminated and limited outcome data was reported.
- Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Trial initiation date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Terminated; Due to inadequate accrual, study was terminated and limited outcome data was reported. Initiation date: Mar 2013 --> Sep 2013
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment change: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Dec 11, 2013
P1/2, N=6, Not yet recruiting, Sponsor: Isofol Medical AB
Initiation date: Mar 2013 --> Sep 2013 N=12 --> 6
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: SWOG-S0600: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy (clinicaltrials.gov) - Dec 11, 2013
P3, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
N=12 --> 6 N=1260 --> 72
- Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Enrollment open, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
N=1260 --> 72 Not yet recruiting --> Recruiting
- | pegilodecakin (LY3500518) / Eli Lilly
New P1 trial: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Dec 10, 2013
P1, N=45, Recruiting, Sponsor: ARMO BioSciences
- | New P2 trial: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Dec 9, 2013
P2, N=222, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Trial termination, Metastases: FOLFIRINOX in Patients With Inoperable Pancreatic Cancer (clinicaltrials.gov) - Dec 8, 2013
P2, N=25, Terminated, Sponsor: University of Oklahoma
Not yet recruiting --> Recruiting Recruiting --> Terminated; The principal investigator terminated the study due to inactivity and low enrollment
- Tepezza (teprotumumab-trbw) / Roche, Amgen
Trial termination: A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 8, 2013
P1, N=104, Terminated, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated; The principal investigator terminated the study due to inactivity and low enrollment Completed --> Terminated
- Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2013
P1, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2013
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
- | tigatuzumab (CS-1008) / Daiichi Sankyo
Trial completion, Combination therapy, Metastases: Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments (clinicaltrials.gov) - Dec 1, 2013
P1, N=21, Completed, Sponsor: Daiichi Sankyo Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (clinicaltrials.gov) - Nov 30, 2013
P2, N=72, Active, not recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed N=55 --> 72
- Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (clinicaltrials.gov) - Nov 30, 2013
P2, N=72, Active, not recruiting, Sponsor: Fudan University
N=55 --> 72 Recruiting --> Active, not recruiting
- Enrollment open, Metastases: MATURE01: Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer (clinicaltrials.gov) - Nov 28, 2013
P=N/A, N=47, Recruiting, Sponsor: International Group of Endovascular Oncology
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche
New P3 trial, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Nov 25, 2013
P3, N=600, Recruiting, Sponsor: Epidemiological and Clinical Research Information Network
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: FLOX + Cetuximab (Erbitux (clinicaltrials.gov) - Nov 25, 2013
P2, N=152, Completed, Sponsor: Odense University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery: Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed (clinicaltrials.gov) - Nov 25, 2013
P3, N=1800, Completed, Sponsor: Medical Research Council
Recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial initiation date, Surgery, Metastases: Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer (clinicaltrials.gov) - Nov 21, 2013
P2, N=39, Recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Initiation date: Oct 2010 --> Apr 2011
- ||||| Vectibix (panitumumab) / Amgen
New P2 trial: PanaMa: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 21, 2013
P2, N=280, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 20, 2013
P2, N=92, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Oct 2010 --> Apr 2011 Not yet recruiting --> Recruiting
- || telisotuzumab (h224G11) / AbbVie
Enrollment change, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 19, 2013
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting N=73 --> 124
- Modufolin (arfolitixorin) / Isofol Medical, Solasia
New P1/2 trial: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=6, Not yet recruiting, Sponsor: Isofol Medical AB
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial suspension, Combination therapy, Metastases: PEPCOL: Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2013
P2, N=55, Suspended, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
N=73 --> 124 Recruiting --> Suspended
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Combination therapy, Metastases: PEPCOL: Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2013
P2, N=55, Suspended, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Suspended N=88 --> 55
- | Avastin (bevacizumab) / Roche
New P1/2 trial, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=24, Recruiting, Sponsor: Randall F. Holcombe
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Oxaliplatin and Bevacizumab (Avastin (clinicaltrials.gov) - Oct 31, 2013
P3, N=0, Completed, Sponsor: Prologue Research International
N=88 --> 55 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery: High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer (clinicaltrials.gov) - Oct 31, 2013
P3, N=0, Completed, Sponsor: Robert Roessle Comprehensive Cancer Center - Charite Campus Buch
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial suspension: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors (clinicaltrials.gov) - Oct 29, 2013
P3, N=190, Suspended, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche
New P4 trial, Combination therapy: Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases (clinicaltrials.gov) - Oct 28, 2013
P4, N=300, Recruiting, Sponsor: Xu jianmin
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
New P4 trial: Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer (clinicaltrials.gov) - Oct 28, 2013
P4, N=300, Recruiting, Sponsor: Xu jianmin
- Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial completion, Metastases: Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. (clinicaltrials.gov) - Oct 28, 2013
P2, N=54, Completed, Sponsor: Regione Lombardia
Recruiting --> Suspended Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., celecoxib oral / Generic mfg.
Trial completion, Combination therapy: Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon (clinicaltrials.gov) - Oct 27, 2013
P3, N=0, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 26, 2013
P2, N=49, Not yet recruiting, Sponsor: Jilin Provincial Tumor Hospital
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab (clinicaltrials.gov) - Oct 24, 2013
P1, N=198, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly
Trial initiation date, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2013
P1, N=21, Terminated, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Initiation date: Sep 2008 --> Jan 2009
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, IO biomarker, Metastases: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer (clinicaltrials.gov) - Oct 20, 2013
P1, N=21, Terminated, Sponsor: EMD Serono
Initiation date: Sep 2008 --> Jan 2009 N=30 --> 21
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion: Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed (clinicaltrials.gov) - Oct 16, 2013
P3, N=2500, Completed, Sponsor: Institute of Cancer Research, United Kingdom
N=30 --> 21 Active, not recruiting --> Completed
- New P2 trial, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Oct 15, 2013
P2, N=26, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- | New P1/2 trial, Metastases: GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - Oct 15, 2013
P1/2, N=60, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
- Enrollment open, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Oct 15, 2013
P2, N=26, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 14, 2013
P2, N=47, Active, not recruiting, Sponsor: Centre Jean Perrin
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Oct 14, 2013
P2, N=57, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open, Metastases: GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - Oct 13, 2013
P1/2, N=60, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 10, 2013
P2, N=47, Active, not recruiting, Sponsor: Centre Jean Perrin
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- Enrollment open: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Oct 9, 2013
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
New P2 trial, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 8, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
- | pegvorhyaluronidase alfa (PEGPH20) / Halozyme
New P1/2 trial, Metastases: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 7, 2013
P1/2, N=172, Recruiting, Sponsor: Southwest Oncology Group
- ||||| Enrollment closed: Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 7, 2013
P3, N=393, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Completed --> Active, not recruiting